In real life, performance of lateral-flow-based antigen tests are well below the manufacturer's specifications, irrespective of patient's symptoms. Their use for detection of individual patients infected with SARS-CoV2 should be discouraged. This does not preclude their usefulness in large-scale screening programs to reduce transmission events on a population-wide scale.
No takes yet. Share an insight, caveat, or question.
Kahn et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: